WuXi Biologics

PharmaMing Bio (2269.HK) is the world's leading biopharmaceutical CRDMO. Its Chengdu Wenjiang Microbial Commercial Production Base plans 95,000 square meters, focusing on the large-scale production of DS and DP of recombinant proteins such as polypeptides, antibody fragments, enzymes, cytokines, etc., and will land the 'first dual-cavity lyophilized preparation production line in China', jointly built with Weisheng Pharmaceutical, supporting the Xilin bottle line, with an annual production capacity of more than 10 million preparations. It is expected that GMP will be put into production by the end of 2026. The dual-cavity cassette bottle (DCD) system is used for the pre-filled injection pen of the long-acting growth hormone lonapegsomatropin, and the lyophilized powder is mixed with the diluent separately and before use. The base is equipped with the EffiX™ Escherichia coli expression platform (yield > 15g/L), and the Wuxi, Shanghai, and Hangzhou bases can provide end-to-end services from strain development to commercialization. The quality system complies with FDA, EMA, NMPA and other cGMP, and has passed official verification in Europe, the United States and China many times, serving 900 + clinical and commercial projects worldwide.